Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) reported complete Phase 1/2 multidose data for VGA039 (latarcibart), a Protein S‑targeting investigational monoclonal antibody for von Willebrand disease (VWD), in 16 patients presented at ISTH 2026.
Latarcibart once‑monthly subcutaneous prophylaxis achieved a median 81% reduction in annualized bleeding rate (ABR) across all VWD types and bleed categories. In patients switching from von Willebrand factor (VWF) IV prophylaxis, bleed reductions were 75–100%. Among patients without prior IV prophylaxis but with historical ABR >12, reductions ranged from 46–100%, with 6 of 7 above 73%. VWF‑treated breakthrough bleeds were reduced by about 86%, and 70% of patients with prior VWF‑treated bleeds had none on treatment.
Latarcibart was reported as safe and well tolerated over six doses; three related treatment‑emergent adverse events (two Grade 2 headaches in one patient, one Grade 1 injection site reaction) and one unrelated serious GI bleed occurred. All participants with substantial baseline bleed burden continued into an open‑label extension. A pivotal Phase 3 VIVID‑6 trial in VWD is currently enrolling.
Incyte (Nasdaq: INCY) will release its Q2 2026 financial results on July 28, 2026. The press release is scheduled for 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.
Investors can join via domestic or international dial-in, or access a live webcast with slides on the company’s investor relations website. Phone replay will be available for 30 days, and webcast replay for 90 days.
Incyte (Nasdaq: INCY) completed its acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront, plus up to $750 million in sales milestones. The deal adds VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio.
VGA039 has multiple U.S. FDA designations and is being studied as a once‑monthly subcutaneous prophylactic therapy in the global Phase 3 VIVID-6 trial. Incyte expects to record the transaction as a one-time R&D expense in Q3 and full-year 2026 GAAP and non-GAAP results.
Star Therapeutics, a late clinical-stage biotech, will present complete Phase 1/2 multidose data for VGA039 in von Willebrand disease at the ISTH 2026 Congress in Paris (July 11-15, 2026). VGA039, a Protein S-targeting monoclonal antibody in Phase 3 pivotal development, is being studied as a once-monthly subcutaneous prophylactic for all VWD types.
Earlier in June, Incyte (Nasdaq: INCY) agreed to acquire Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestones, adding VGA039 to its hematology portfolio for up to $2.0 billion total consideration.
Incyte (Nasdaq: INCY) announced a positive CHMP opinion recommending EU approval of Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis (AD) inadequately controlled by topical corticosteroids and calcineurin inhibitors.
Phase 3 TRuE‑AD4 showed significant EASI75 and IGA-TS responses, sustained control to Week 24, and a favorable 24‑week safety profile. The European Commission will now review the opinion, potentially granting a second EU indication after non-segmental vitiligo.
Incyte (NASDAQ:INCY) announced that Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) plus lenalidomide to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
Approval is supported by Phase II L-MIND and Phase Ib/II J-MIND trial results showing response rates up to 71.4%. According to Incyte, Minjuvi plus lenalidomide delivered clinically meaningful responses with manageable side effects, mainly neutropenia and thrombocytopenia. This is Minjuvi’s second approval in Japan.
Mirum Pharmaceuticals (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) reported pivotal Phase 2 PROGRESS data for zilurgisertib in fibrodysplasia ossificans progressiva (FOP). In 63 patients ≥12 years, zilurgisertib showed large reductions in new and existing heterotopic ossification (HO) lesion volume and maintained low flare activity through Week 48. Zilurgisertib was generally well tolerated, with mainly mild to moderate adverse events. The FDA accepted the NDA with Priority Review for FOP patients ≥12 years, with a PDUFA target action date of September 26, 2026.
Incyte (Nasdaq:INCY) reported updated Phase 1 data for INCA033989, a first-in-class mutant calreticulin antibody, in myelofibrosis (MF) and essential thrombocythemia (ET).
INCA033989 showed rapid, durable clinical and molecular responses with high spleen, symptom, anemia and hematologic response rates and generally manageable safety, and has FDA Breakthrough Therapy designation in ET and a Phase 3 ET trial starting mid-2026.
Incyte (Nasdaq: INCY) reported pivotal Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide added to R-CHOP in previously untreated high-risk DLBCL and HGBL.
Tafa-Len-R-CHOP cut risk of progression or death by 25%, improved PFS and EFS, raised MRD-negativity rates, and showed manageable but higher Grade ≥3 and fatal adverse events, supporting global regulatory applications.
Incyte (Nasdaq: INCY) agreed to acquire Vega Therapeutics, a wholly owned Star Therapeutics subsidiary, for $1.25 billion upfront, plus up to $750 million in sales milestones, for potential consideration of $2.0 billion.
The deal adds VGA039, a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease, with multiple FDA designations. Closing is expected in Q3 2026, triggering an estimated $1.25 billion R&D charge to Incyte’s 2026 GAAP and non-GAAP results.